SC
ANIP icon

Stempoint Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Stempoint Capital’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-85,382
Closed -$4.71M – 66
2023
Q4 		$4.71M Buy
+85,382
New +$4.7M 1.26% 31

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stempoint Capital's ANIP Position: Q1 2024 in Review

Stempoint Capital sold out of ANI Pharmaceuticals (ANIP) in Q1 2024, closing a stake of 85,382 shares — an estimated $4.71M sold.

Stempoint Capital first reported a position in ANIP in Q4 2023 and held it in 1 quarter. The position peaked at $4.71M in Q4 2023. 200 funds tracked by Wall St. Rank hold ANIP as of Q1 2024.

  • Stempoint Capital reported no remaining ANI Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Stempoint Capital sold 85,382 ANI Pharmaceuticals shares in Q1 2024, an estimated $4.71M.
  • Stempoint Capital first reported a position in ANI Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Stempoint Capital's ANI Pharmaceuticals position peaked at $4.71M in Q4 2023.
  • 200 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2024.

Based on Stempoint Capital's 13F filing for Q1 2024, filed 14 May 2024.